Synthesis of Anti-Metastatic Agent for Cancer Theraphy

DSpace/Manakin Repository

Show simple item record

dc.contributor.advisor Scarso, Alessandro it_IT
dc.contributor.author Shehata, Sara <1993> it_IT
dc.date.accessioned 2018-10-07 it_IT
dc.date.accessioned 2019-02-19T15:13:51Z
dc.date.issued 2018-10-23 it_IT
dc.identifier.uri http://hdl.handle.net/10579/13854
dc.description.abstract Breast cancer is the most common cancer in women worldwide and is the cause of millions of deaths around the world each year. The majority of breast cancer related mortalities are a result of metastatic disease involving the formation of secondary tumours where cancer cells have spread from the primary tumour to sites around the body. Among the most difficult to treat are those which belong to the basal-type, or triple-negative intrinsic molecular class as these lack the three key hormone receptors: oestrogen (ER), progesterone (PGR) and human epithelial receptor 2 (Her2) which are the targets of many of the existing, well-established targeted cancer therapeutics. Although there has been progress towards the discovery of a targeted drug for the treatment of metastatic, advanced breast cancer, to date there still remains limited options. A current area of research interest in the treatment of metastatic disease has focused on the role in which chronic stress plays in tumour progression and the formation of metastases. Subsequently, a number of laboratory studies have shown that stress hormones play a crucial role in the progression of breast cancer and the formation of secondary tumours. It is now known that the action of stress is mediated through the stimulation of the β2-adrenergic receptor by the neurotransmitter and stress hormone norepinephrine. Furthermore, breast cancers have been found to express elevated levels of the β2-adrenergic receptor, and interestingly, the hard-to-treat basal-type (triple-negative) molecular class of breast cancers have been found to express the highest levels compared to other molecular classes. Crucially, further studies have shown that the pro-metastatic influence of stress (via stimulation of the β2-adrenergic receptor) can be blocked by β-adrenoceptor antagonists such as Propranolol. Therefore, the retardation and potential inhibition of stress-induced breast cancer metastasis by blockade of the β2-adrenergic receptor is a potentially promising therapeutic target option. it_IT
dc.language.iso en it_IT
dc.publisher Università Ca' Foscari Venezia it_IT
dc.rights © Sara Shehata, 2018 it_IT
dc.title Synthesis of Anti-Metastatic Agent for Cancer Theraphy it_IT
dc.title.alternative Synthesis of New Anti-Metastatic Agent for Cancer Therapy it_IT
dc.type Bachelor Thesis it_IT
dc.degree.name Chimica e tecnologie sostenibili it_IT
dc.degree.level Laurea magistrale it_IT
dc.degree.grantor Dipartimento di Scienze Molecolari e Nanosistemi it_IT
dc.description.academicyear 2017/2018, lauree sessione autunnale it_IT
dc.rights.accessrights closedAccess it_IT
dc.thesis.matricno 843990 it_IT
dc.subject.miur CHIM/06 CHIMICA ORGANICA it_IT
dc.description.note it_IT
dc.degree.discipline it_IT
dc.contributor.co-advisor it_IT
dc.date.embargoend 10000-01-01
dc.provenance.upload Sara Shehata (843990@stud.unive.it), 2018-10-07 it_IT
dc.provenance.plagiarycheck Alessandro Scarso (alesca@unive.it), 2018-10-22 it_IT


Files in this item

This item appears in the following Collection(s)

Show simple item record